23-valent pneumococcal polysaccharide vaccine
PPV23-2021-2
Approved mab completed
Quick answer
23-valent pneumococcal polysaccharide vaccine for Vaccination is a Approved program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Vaccination
- Phase
- Approved
- Modality
- mab
- Status
- completed